Cumberland closes $100 million asset sale to Apotex, keeps rare disease pipeline

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced on July 1, 2026 that it had closed a transaction with a subsidiary of Apotex Health Corp. to integrate their branded U.S. businesses.¹ Under the terms disclosed in the 8-K, Cumberland completed the sale of the Assets to Nuvo and certain affiliates of Apotex for aggregate cash consideration of $100 million pursuant to the terms of the Agreement.¹

The transaction was carried out under an Asset Purchase Agreement dated April 22, 2026 among Cumberland, Nuvo Pharmaceuticals (Ireland) DAC, and Apotex. Through this agreement, Nuvo and certain affiliates of Apotex acquired the company's FDA-approved products, named Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ, along with certain related equity interests.¹ On July 1, 2026, the parties also signed Amendment No. 1 to exclude certain contracts from the Assets being transferred to Nuvo in the Transaction.¹

Shareholders backed the deal by a wide margin: CEO A.J. Kazimi said the transaction was strongly supported by our shareholders with over 99% of the votes cast in favor of the transaction.¹ The special meeting approving the sale was held on June 24, 2026, as described in the definitive proxy statement filed by the Company with the SEC on May 26, 2026.¹

Separately, in connection with closing, on June 29, 2026 Cumberland terminated and repaid in full all outstanding obligations, approximately $5.3 million, due under its Revolving Credit Loan Agreement with Pinnacle Bank dated September 5, 2023.¹

Cumberland said it retained its portfolio of product candidates and its majority ownership position in Cumberland Emerging Technologies Inc.¹ Going forward, the company plans to focus on ifetroban, which is being studied in Duchenne muscular dystrophy cardiomyopathy, systemic sclerosis, idiopathic pulmonary fibrosis, and cancer metastasis, according to the release.